46,411 Shares in Tempus AI, Inc. $TEM Bought by Headlands Technologies LLC

Key Points

• Headlands Technologies purchased 46,411 shares of Tempus AI worth approximately $2.69 million, while institutional investors collectively own 24.22% of the company.
• Tempus AI’s latest quarterly results exceeded expectations, with a loss of $0.04 per share versus the estimated $0.14 loss and revenue of $382.49 million, up 21.6% year over year.
• Analyst sentiment is mixed: the stock has an average “Hold” rating and a $65.69 price target, while insiders have sold more than 1 million shares worth about $56.8 million over the past 90 days.

Headlands Technologies LLC purchased a new position in Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 46,411 shares of the company's stock, valued at approximately $2,689,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JPL Wealth Management LLC bought a new position in shares of Tempus AI during the third quarter worth about $26,000. Los Angeles Capital Management LLC acquired a new stake in Tempus AI during the fourth quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd acquired a new stake in Tempus AI during the third quarter valued at approximately $38,000. Whittier Trust Co. lifted its holdings in Tempus AI by 190.0% during the 1st quarter. Whittier Trust Co. now owns 870 shares of the company's stock worth $41,000 after buying an additional 570 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in shares of Tempus AI by 88.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 691 shares of the company's stock worth $44,000 after acquiring an additional 325 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company's stock.

Tempus AI Price Performance

TEM opened at $64.04 on Monday. The stock's 50 day moving average price is $54.63 and its 200 day moving average price is $51.76. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The stock has a market cap of $11.56 billion, a P/E ratio of -44.47 and a beta of 3.58. Tempus AI, Inc. has a 12 month low of $40.77 and a 12 month high of $104.32.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm's quarterly revenue was up 21.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.22) EPS. As a group, research analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TEM has been the subject of a number of research reports. TD Cowen reaffirmed a "buy" rating on shares of Tempus AI in a report on Wednesday, July 15th. HC Wainwright decreased their price target on shares of Tempus AI from $64.00 to $56.00 and set a "buy" rating for the company in a report on Monday, August 3rd. Wall Street Zen raised shares of Tempus AI from a "sell" rating to a "hold" rating in a research report on Saturday, July 25th. Weiss Ratings lowered shares of Tempus AI from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday. Finally, Lake Street Capital downgraded Tempus AI to a "hold" rating in a research note on Monday, July 20th. Nine investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, Tempus AI presently has an average rating of "Hold" and an average target price of $65.69.

Insiders Place Their Bets

In related news, CFO James William Rogers sold 26,313 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total value of $1,578,780.00. Following the completion of the transaction, the chief financial officer owned 106,024 shares in the company, valued at $6,361,440. This represents a 19.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric P. Lefkofsky sold 11,848 shares of the firm's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $69.87, for a total transaction of $827,819.76. Following the transaction, the chief executive officer directly owned 150,000 shares in the company, valued at approximately $10,480,500. The trade was a 7.32% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,040,988 shares of company stock valued at $56,756,417. Corporate insiders own 24.26% of the company's stock.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source